A Study of Tirzepatide (LY3298176) in Chinese Participants With Type 2 Diabetes

NCT05691712 · Completed

Last updated 2026-05-28

This clinical trial is testing the medication tirzepatide in Chinese adults with type 2 diabetes to see how it affects their blood sugar levels over time.

Status Completed The study has finished.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 257 people

Who can join Ages 18+ · all sexes Healthy volunteers accepted.

Timeline Started 2023-02 · est. completion 2024-07

Where 25 sites · China

What this study is testing ClinicalTrials.gov NCT05691712 ↗

Description as written by the study sponsor.

The main purpose of this study is to compare the effect of the addition of tirzepatide or placebo to titrated basal insulin on glycemic control in Chinese participants with type 2 diabetes.

Treatments tested

Tirzepatide also known as LY3298176 Drug

Administered SC
Placebo Drug

Administered SC

Main thing measured	Mean Change From Baseline in HbA1c (Tirzepatide 10 or 15 Milligram [mg])
Sponsor	Eli Lilly and Company
Conditions studied	Diabetes Type 2, Diabetes Mellitus, Glucose Metabolism Disorders, Metabolic Disease, Endocrine System Diseases
GLP-1 drugs	tirzepatide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT05691712 ↗